# A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

> **NCT04260802** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ocellaris Pharma, Inc.** · enrollment: 73 (actual)

## Conditions studied

- Cancer
- Neoplasms
- Metastatic Cancer
- Triple Negative Breast Cancer
- Gastric Cancer
- Cervical Cancer
- Ovarian Cancer
- Hepatocellular Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Urothelial Neoplasm
- Non Small Cell Lung Cancer
- Renal Cell Carcinoma
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Neoplasm
- Squamous Cell Carcinoma
- Sarcoma
- Merkel Cell Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** OC-001
- **DRUG:** Drug: OC-001 in Combination with Avelumab

## Key facts

- **NCT ID:** NCT04260802
- **Lead sponsor:** Ocellaris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-24
- **Primary completion:** 2025-11-07
- **Final completion:** 2025-11-07
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260802, "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04260802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*